DoH Policies screened during the period: 1st October 2020 - 31st December 2020
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact
Documents
- The establishment of a regional service delivery model for daycase elective care procedures in Northern Ireland (PDF 824KB)
- The establishment of a regional service delivery model elective orthopaedic care in Northern Ireland (PDF 868KB)
- The Quality and Safety of Organs Intended for Transplantation (Amendment) (EU Exit) Regulations 2020 (PDF 428KB)
- The Blood Safety and Quality (Amendment) (EU Exit) Regulations 2020 (PDF 42KB)
- The Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit) Regulations 2020 (PDF 430KB)
- The Reciprocal and Cross-Border Healthcare (Amendment etc) (EU Exit) Regulations 2020 (PDF 421KB)
- NICE Technology Appraisal TA649 - Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (PDF 438KB)
- NICE Technology Appraisal TA651 - Naldemedine for treating opioid-induced constipation (PDF 327KB)
- NICE Technology Appraisal TA650 - Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (PDF 326KB)
- NICE Technology Appraisal TA653 - Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (review of TA416) (PDF 340KB)
- NICE Technology Appraisal TA655 - Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (review of TA483) (PDF 340KB)
- NICE Technology Appraisal TA654 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (rapid review of TA621) (PDF 340KB)
- NICE Technology Appraisal TA656 - Siponimod for treating secondary progressive multiple sclerosis (PDF 328KB)
- NICE Technology Appraisal TA658 - Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (PDF 339KB)
- NICE Technology Appraisal TA660 - Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (PDF 327KB)
- NICE Technology Appraisal TA661 - Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (PDF 341KB)
- NICE Technology Appraisal TA657 - Carfilzomib for previously treated multiple myeloma (part review of TA457) (PDF 340KB)
- NICE Technology Appraisal TA659 - Galcanezumab for preventing migraine (PDF 340KB)
- Provision of Health Services to Persons Not Ordinarily Resident (Amendment) (No. 2) Regulations (Northern Ireland) 2020 (PDF 534KB)